UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 2014, Volume 311, Issue 18, pp. 1870 - 1882
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Dyslipidemias - drug therapy | Double-Blind Method | Pyrimidines - administration & dosage | Simvastatin - administration & dosage | Humans | Middle Aged | Ezetimibe | Rosuvastatin Calcium | Antibodies, Monoclonal - therapeutic use | Male | Treatment Outcome | Fluorobenzenes - administration & dosage | Hypercholesterolemia - drug therapy | Atorvastatin Calcium | Azetidines - therapeutic use | Pyrroles - administration & dosage | Anticholesteremic Agents - administration & dosage | Heptanoic Acids - administration & dosage | Female | Aged | Drug Therapy, Combination | Sulfonamides - administration & dosage | Side effects | Monoclonal antibodies | Clinical trials | Drug therapy | Low density lipoprotein | Statins | Cholesterol
Journal Article
American journal of clinical dermatology, ISSN 1175-0561, 06/2016, Volume 17, Issue 3, pp. 191 - 200
Life Sciences & Biomedicine | Dermatology | Science & Technology | Humans | Protein Kinase Inhibitors - adverse effects | Thiazoles - adverse effects | Thalidomide - analogs & derivatives | Isonicotinic Acids - administration & dosage | Phosphodiesterase 4 Inhibitors - adverse effects | Pyrroles - administration & dosage | Adenosine - adverse effects | Adamantane - therapeutic use | Pyrroles - adverse effects | Adamantane - administration & dosage | Receptors, Lysosphingolipid - metabolism | Adamantane - analogs & derivatives | Isonicotinic Acids - adverse effects | Thalidomide - adverse effects | Biological Therapy | Isonicotinic Acids - therapeutic use | Piperidines - administration & dosage | Psoriasis - drug therapy | Adenosine A3 Receptor Antagonists - therapeutic use | Administration, Oral | Azetidines - adverse effects | Niacinamide - adverse effects | Niacinamide - therapeutic use | Phosphodiesterase 4 Inhibitors - therapeutic use | Adenosine A3 Receptor Antagonists - adverse effects | Thalidomide - administration & dosage | Adenosine - administration & dosage | Protein Kinase Inhibitors - administration & dosage | Azetidines - therapeutic use | Adenosine - analogs & derivatives | Thalidomide - therapeutic use | Sulfonamides - administration & dosage | Niacinamide - analogs & derivatives | Thiazoles - administration & dosage | Thiazoles - therapeutic use | rho-Associated Kinases - antagonists & inhibitors | Phosphodiesterase 4 Inhibitors - administration & dosage | Adenosine - therapeutic use | Arthritis, Psoriatic - drug therapy | Pyrroles - therapeutic use | Adamantane - adverse effects | Adenosine A3 Receptor Antagonists - administration & dosage | Pyrimidines - administration & dosage | Clinical Trials as Topic | Niacinamide - administration & dosage | Biological Factors - therapeutic use | Janus Kinases - antagonists & inhibitors | Azetidines - administration & dosage | Sulfonamides - therapeutic use | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Piperidines - adverse effects | Pyrimidines - adverse effects | Sulfonamides - adverse effects
Journal Article
Cochrane library, ISSN 1469-493X, 2015, Volume 2015, Issue 11, pp. CD010956 - CD010956
Pyridines | Anticoagulants | Factor Xa Inhibitors | Administration, Oral | Pyrazoles | Medical treatment | Pyridones | Venous Thrombosis | Deep vein thrombosis | Dabigatran | Randomized Controlled Trials as Topic | Rivaroxaban | Antithrombins | Treatment | Deep vein thrombosis (DVT) related | Thiazoles | Benzylamines | Heart & circulation | Medicine General & Introductory Medical Sciences | Thromboembolism | Azetidines | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Dabigatran - administration & dosage | Pyridines - administration & dosage | Venous Thrombosis - drug therapy | Humans | Thiazoles - administration & dosage | Antithrombins - administration & dosage | Benzylamines - administration & dosage | Rivaroxaban - administration & dosage | Factor Xa Inhibitors - administration & dosage | Pyridones - administration & dosage | Pyrazoles - administration & dosage | Azetidines - administration & dosage | Index Medicus
Journal Article
Pharmacotherapy, ISSN 0277-0008, 05/2020, Volume 40, Issue 5, pp. 416 - 437
dialysis | renal | antivirals | cytochrome P450 | infectious disease | liver | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Pandemics | Alanine - adverse effects | Adrenal Cortex Hormones | Coronavirus Infections - drug therapy | Humans | Pneumonia, Viral - drug therapy | Thiazoles - administration & dosage | Hydroxychloroquine - adverse effects | Thiazoles - adverse effects | Alanine - analogs & derivatives | Alanine - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Ritonavir - adverse effects | Ribavirin - administration & dosage | Betacoronavirus | Antibodies, Monoclonal, Humanized - adverse effects | Ritonavir - administration & dosage | Immunomodulation | Azetidines - adverse effects | Chloroquine - adverse effects | Antiviral Agents - administration & dosage | Adenosine Monophosphate - adverse effects | Hydroxychloroquine - administration & dosage | Nelfinavir - adverse effects | Interferon-alpha - administration & dosage | Azetidines - administration & dosage | Ribavirin - adverse effects | Adenosine Monophosphate - administration & dosage | Adenosine Monophosphate - analogs & derivatives | Antiviral Agents - adverse effects | Coronavirus Infections - therapy | Immunization, Passive | Lopinavir - administration & dosage | Sulfonamides - adverse effects | Chloroquine - administration & dosage | Interferon-alpha - adverse effects | Nelfinavir - administration & dosage | Drug Combinations | Lopinavir - adverse effects | Sulfonamides - administration & dosage | Severe acute respiratory syndrome coronavirus 2 | COVID-19 | Antiviral agents | Therapeutic applications | Clinical trials | Coronaviruses | Drug therapy | Patients | Index Medicus | Reviews of Therapeutics | Review of Therapeutics
Journal Article
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 02/2005, Volume 293, Issue 6, pp. 681 - 689
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Prodrugs - administration & dosage | Recurrence | Anticoagulants - administration & dosage | Humans | Middle Aged | Male | Venous Thrombosis - complications | Heparin, Low-Molecular-Weight - therapeutic use | Warfarin - administration & dosage | Warfarin - therapeutic use | Aged, 80 and over | Adult | Female | Drug Therapy, Combination | Pulmonary Embolism - complications | Double-Blind Method | Venous Thrombosis - drug therapy | Venous Thrombosis - mortality | Anticoagulants - therapeutic use | Treatment Outcome | Azetidines - administration & dosage | Azetidines - therapeutic use | Benzylamines | Aged | Prodrugs - therapeutic use | Alanine Transaminase - metabolism | Heparin, Low-Molecular-Weight - administration & dosage | Clinical trials | Cardiac arrhythmia | Thrombolytic drugs | Medical treatment | Blood clots
Journal Article
The oncologist (Dayton, Ohio), ISSN 1083-7159, 07/2017, Volume 22, Issue 7, pp. 823 - 833
BRAF | Mitogen‐activated protein kinase signaling system | Drug‐related side effects and adverse reactions | Protein kinase inhibitors | Melanoma | Mitogen-activated protein kinase signaling system | Drug-related side effects and adverse reactions | Life Sciences & Biomedicine | Oncology | Science & Technology | Oximes - adverse effects | Humans | Fever - therapy | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Carbamates - administration & dosage | Protein Kinase Inhibitors - adverse effects | Fever - chemically induced | Pyridones - administration & dosage | Benzimidazoles - administration & dosage | Antineoplastic Agents - adverse effects | Benzimidazoles - adverse effects | Skin Diseases - chemically induced | Piperidines - administration & dosage | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Azetidines - adverse effects | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Melanoma - pathology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Vemurafenib | Azetidines - administration & dosage | Indoles - adverse effects | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Piperidines - adverse effects | Sulfonamides - adverse effects | Carbamates - adverse effects | Pyrimidinones - administration & dosage | Pyridones - adverse effects | Sulfonamides - administration & dosage | Index Medicus | Melanoma and Cutaneous Malignancies
Journal Article
Blood, ISSN 0006-4971, 09/2017, Volume 130, Issue 11, pp. 1377 - 1380
Life Sciences & Biomedicine | Hematology | Science & Technology | Erdheim-Chester Disease - diagnostic imaging | Follow-Up Studies | Humans | Oximes - administration & dosage | Imidazoles - administration & dosage | Oximes - therapeutic use | Molecular Targeted Therapy | Indoles - administration & dosage | Multicenter Studies as Topic | Registries | Retrospective Studies | Imidazoles - therapeutic use | France | Erdheim-Chester Disease - genetics | Piperidines - administration & dosage | Drug Administration Schedule | Treatment Outcome | Positron Emission Tomography Computed Tomography | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Vemurafenib | Erdheim-Chester Disease - drug therapy | Azetidines - administration & dosage | Azetidines - therapeutic use | Sulfonamides - therapeutic use | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Indoles - therapeutic use | Sulfonamides - administration & dosage | Index Medicus | Abridged Index Medicus
Journal Article
Mayo Clinic proceedings, ISSN 0025-6196, 07/2020, Volume 95, Issue 7, pp. 1404 - 1419
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Piperidines - administration & dosage | Drug Administration Schedule | Pyrimidines - administration & dosage | Humans | Azetidines - adverse effects | Purines - administration & dosage | Randomized Controlled Trials as Topic | Dose-Response Relationship, Drug | Janus Kinase Inhibitors - adverse effects | Pyrazoles - administration & dosage | Azetidines - administration & dosage | Janus Kinase Inhibitors - administration & dosage | Arthritis, Rheumatoid - drug therapy | Heterocyclic Compounds, 3-Ring - administration & dosage | Heterocyclic Compounds, 3-Ring - adverse effects | Piperidines - adverse effects | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Purines - adverse effects | Sulfonamides - administration & dosage | Pyrazoles - adverse effects | Infection | Complications and side effects | Rheumatoid factor | Tofacitinib | Analysis | Arthritis | Thromboembolism | Cytokines | Pathogenesis | Bias | Rheumatology | Clinical trials | Systematic review | Infections | Patients | Meta-analysis | Studies | Rheumatoid arthritis | Questionnaires | TNF inhibitors | Tumor necrosis factor-TNF | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 11/2014, Volume 371, Issue 20, pp. 1867 - 1876
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Indoles - administration & dosage | Melanoma - genetics | Adult | Female | MAP Kinase Kinase 1 - antagonists & inhibitors | Piperidines - administration & dosage | Azetidines - adverse effects | Kaplan-Meier Estimate | Survival Rate | Melanoma - secondary | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Disease-Free Survival | Azetidines - administration & dosage | Indoles - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Piperidines - adverse effects | Sulfonamides - adverse effects | Aged | Mutation | Sulfonamides - administration & dosage | Melanoma - mortality | Vemurafenib | Treatment outcome | Usage | Care and treatment | Analysis | Melanoma | Dosage and administration | Drug therapy, Combination | Risk factors | Chemotherapy | Toxicity | MEK inhibitors | Metastasis | Kinases | Survival | Metastases | Tumors | Index Medicus | Abridged Index Medicus
Journal Article